Pfizer Inc. confirmed the agreement to buy the US cancer drug firm, Medivation, for about $14 billion in cash With this acquisition, the American pharmaceutical giant, will add one of the leading prostate-cancer drugs called Xandi to its oncology portfolio Xandi already generates about $2 billion and is expected to generate $5.7 billion in sales by 2020 "The addition of Medivation will strengthen Pfizer's Innovative Health business and accelerate its pathway to a leadership position in oncology" Pfizer CEO Ian Read said